Abstract

Hereditary hemorrhagic telangiectasia (HHT) management is evolving because of the emergence and development of antiangiogenic therapies to eliminate bleeding telangiectasias and achieve hemostasis. This progress is reflected in recent clinical recommendations published in the Second International Guidelines for the Diagnosis and Treatment of HHT, in which systemic therapies including antiangiogenics and antifibrinolytics are now recommended as standard treatment options for bleeding. This review highlights the new recommendations especially relevant to hematologists in managing bleeding, anticoagulation, and anemia in patients with HHT.

REFERENCES

REFERENCES
1.
Sutton
HG
.
Epistaxis as an indication of impaired nutrition and of degeneration of the vascular system
.
Med Mirror
.
1864
;
1
:
769
-
781
.
2.
Rendu
H
.
Épistaxis répétées chez un sujet porteur de petits angiomes cutanés et muqueux [Repeated epistaxis in a subject with small skin and mucous angiomas]
.
Bull Mem Soc Med Hop Paris
.
1896
;
13
:
731
-
733
.
3.
Leung
DW
,
Cachianes
G
,
Kuang
WJ
,
Goeddel
DV
,
Ferrara
N
.
Vascular endothelial growth factor is a secreted angiogenic mitogen
.
Science
.
1989
;
246
(
4935
):
1306
-
1309
.
4.
Ferrara
N
,
Henzel
WJ
.
Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells
.
Biochem Biophys Res Commun
.
1989
;
161
(
2
):
851
-
858
.
5.
Cirulli
A
,
Liso
A
,
D’Ovidio
F
, et al
.
Vascular endothelial growth factor serum levels are elevated in patients with hereditary hemorrhagic telangiectasia
.
Acta Haematol
.
2003
;
110
(
1
):
29
-
32
.
6.
Faughnan
ME
,
Mager
JJ
,
Hetts
SW
, et al
.
Second International Guidelines for the Diagnosis and Management of Hereditary Hemorrhagic Telangiectasia
.
Ann Intern Med
.
2020
;
M20
-
1443
.
7.
AAssar
OS
,
Friedman
CM
,
White
RI
Jr.
,
OS
AA
.
The natural history of epistaxis in hereditary hemorrhagic telangiectasia
.
Laryngoscope
.
1991
;
101
(
9
):
977
-
980
.
8.
Kritharis
A
,
Al-Samkari
H
,
Kuter
DJ
.
Hereditary hemorrhagic telangiectasia: diagnosis and management from the hematologist’s perspective
.
Haematologica
.
2018
;
103
(
9
):
1433
-
1443
.
9.
Faughnan
ME
,
Palda
VA
,
Garcia-Tsao
G
, et al;
HHT Foundation International - Guidelines Working Group
.
International guidelines for the diagnosis and management of hereditary haemorrhagic telangiectasia
.
J Med Genet
.
2011
;
48
(
2
):
73
-
87
.
10.
Gaillard
S
,
Dupuis-Girod
S
,
Boutitie
F
, et al;
ATERO Study Group
.
Tranexamic acid for epistaxis in hereditary hemorrhagic telangiectasia patients: a European cross-over controlled trial in a rare disease
.
J Thromb Haemost
.
2014
;
12
(
9
):
1494
-
1502
.
11.
Geisthoff
UW
,
Seyfert
UT
,
Kübler
M
,
Bieg
B
,
Plinkert
PK
,
König
J
.
Treatment of epistaxis in hereditary hemorrhagic telangiectasia with tranexamic acid - a double-blind placebo-controlled cross-over phase IIIB study
.
Thromb Res
.
2014
;
134
(
3
):
565
-
571
.
12.
Thalgott
JH
,
Dos-Santos-Luis
D
,
Hosman
AE
, et al
.
Decreased Expression of Vascular Endothelial Growth Factor Receptor 1 Contributes to the Pathogenesis of Hereditary Hemorrhagic Telangiectasia Type 2
.
Circulation
.
2018
;
138
(
23
):
2698
-
2712
.
13.
Han
C
,
Choe
SW
,
Kim
YH
, et al
.
VEGF neutralization can prevent and normalize arteriovenous malformations in an animal model for hereditary hemorrhagic telangiectasia 2
.
Angiogenesis
.
2014
;
17
(
4
):
823
-
830
.
14.
Lebrin
F
,
Srun
S
,
Raymond
K
, et al
.
Thalidomide stimulates vessel maturation and reduces epistaxis in individuals with hereditary hemorrhagic telangiectasia
.
Nat Med
.
2010
;
16
(
4
):
420
-
428
.
15.
Peng
HL
,
Yi
YF
,
Zhou
SK
,
Xie
SS
,
Zhang
GS
.
Thalidomide Effects in Patients with Hereditary Hemorrhagic Telangiectasia During Therapeutic Treatment and in Fli-EGFP Transgenic Zebrafish Model
.
Chin Med J (Engl)
.
2015
;
128
(
22
):
3050
-
3054
.
16.
Fang
J
,
Chen
X
,
Zhu
B
, et al
.
Thalidomide for Epistaxis in Patients with Hereditary Hemorrhagic Telangiectasia: A Preliminary Study
.
Otolaryngol Head Neck Surg
.
2017
;
157
(
2
):
217
-
221
.
17.
Invernizzi
R
,
Quaglia
F
,
Klersy
C
, et al
.
Efficacy and safety of thalidomide for the treatment of severe recurrent epistaxis in hereditary haemorrhagic telangiectasia: results of a non-randomised, single-centre, phase 2 study
.
Lancet Haematol
.
2015
;
2
(
11
):
e465
-
e473
.
18.
Hosman
A
,
Westermann
CJ
,
Snijder
R
,
Disch
F
,
Mummery
CL
,
Mager
JJ
.
Follow-up of Thalidomide treatment in patients with Hereditary Haemorrhagic Telangiectasia
.
Rhinology
.
2015
;
53
(
4
):
340
-
344
.
19.
Baysal
M
,
Ümit
EG
,
Kırkızlar
HO
,
Özdöver
AC
,
Demir
AM
.
Thalidomide for the Management of Bleeding Episodes in Patients with Hereditary Hemorrhagic Telangiectasia: Effects on Epistaxis Severity Score and Quality of Life
.
Turk J Haematol
.
2019
;
36
(
1
):
43
-
47
.
20.
Al-Samkari
H
,
Kritharis
A
,
Rodriguez-Lopez
JM
,
Kuter
DJ
.
Systemic bevacizumab for the treatment of chronic bleeding in hereditary haemorrhagic telangiectasia
.
J Intern Med
.
2019
;
285
(
2
):
223
-
231
.
21.
Hoag
JB
,
Terry
P
,
Mitchell
S
,
Reh
D
,
Merlo
CA
.
An epistaxis severity score for hereditary hemorrhagic telangiectasia
.
Laryngoscope
.
2010
;
120
(
4
):
838
-
843
.
22.
Iyer
VN
,
Apala
DR
,
Pannu
BS
, et al
.
Intravenous Bevacizumab for Refractory Hereditary Hemorrhagic Telangiectasia-Related Epistaxis and Gastrointestinal Bleeding
.
Mayo Clin Proc
.
2018
;
93
(
2
):
155
-
166
.
23.
Dupuis-Girod
S
,
Ambrun
A
,
Decullier
E
, et al
.
Effect of Bevacizumab Nasal Spray on Epistaxis Duration in Hereditary Hemorrhagic Telangectasia: A Randomized Clinical Trial
.
JAMA
.
2016
;
316
(
9
):
934
-
942
.
24.
Whitehead
KJ
,
Sautter
NB
,
McWilliams
JP
, et al
.
Effect of Topical Intranasal Therapy on Epistaxis Frequency in Patients With Hereditary Hemorrhagic Telangiectasia: A Randomized Clinical Trial
.
JAMA
.
2016
;
316
(
9
):
943
-
951
.
25.
Riss
D
,
Burian
M
,
Wolf
A
,
Kranebitter
V
,
Kaider
A
,
Arnoldner
C
.
Intranasal submucosal bevacizumab for epistaxis in hereditary hemorrhagic telangiectasia: a double-blind, randomized, placebo-controlled trial
.
Head Neck
.
2015
;
37
(
6
):
783
-
787
.
26.
Epperla
N
,
Kapke
JT
,
Karafin
M
,
Friedman
KD
,
Foy
P
.
Effect of systemic bevacizumab in severe hereditary hemorrhagic telangiectasia associated with bleeding
.
Am J Hematol
.
2016
;
91
(
6
):
E313
-
E314
.
27.
Rosenberg
T
,
Fialla
AD
,
Kjeldsen
J
,
Kjeldsen
AD
.
Does severe bleeding in HHT patients respond to intravenous bevacizumab? Review of the literature and case series
.
Rhinology
.
2019
;
57
(
4
):
242
-
251
.
28.
Guilhem
A
,
Fargeton
AE
,
Simon
AC
, et al
.
Intra-venous bevacizumab in hereditary hemorrhagic telangiectasia (HHT): A retrospective study of 46 patients
.
PLoS One
.
2017
;
12
(
11
):
e0188943
.
29.
Dupuis-Girod
S
,
Ginon
I
,
Saurin
JC
, et al
.
Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output
.
JAMA
.
2012
;
307
(
9
):
948
-
955
.
30.
Thompson
AB
,
Ross
DA
,
Berard
P
,
Figueroa-Bodine
J
,
Livada
N
,
Richer
SL
.
Very low dose bevacizumab for the treatment of epistaxis in patients with hereditary hemorrhagic telangiectasia
.
Allergy Rhinol (Providence)
.
2014
;
5
(
2
):
91
-
95
.
31.
Chavan
A
,
Schumann-Binarsch
S
,
Schmuck
B
, et al
.
Emerging role of bevacizumab in management of patients with symptomatic hepatic involvement in Hereditary Hemorrhagic Telangiectasia
.
Am J Hematol
.
2017
;
92
(
11
):
E641
-
E644
.
32.
Al-Samkari
H
,
Kasthuri
RS
,
Parambil
JG
, et al
.
An international, multicenter study of intravenous bevacizumab for bleeding in hereditary hemorrhagic telangiectasia: the InHIBIT-Bleed study [published online ahead of print 16 July 2020]
.
Haematologica
.
doi:10.3324/haematol.2020.261859
.
33.
Yin
LX
,
Reh
DD
,
Hoag
JB
, et al
.
The minimal important difference of the epistaxis severity score in hereditary hemorrhagic telangiectasia
.
Laryngoscope
.
2016
;
126
(
5
):
1029
-
1032
.
34.
Sabbà
C
,
Pasculli
G
,
Lenato
GM
, et al
.
Hereditary hemorrhagic telangiectasia: clinical features in ENG and ALK1 mutation carriers
.
J Thromb Haemost
.
2007
;
5
(
6
):
1149
-
1157
.
35.
van Tuyl
SA
,
Letteboer
TG
,
Rogge-Wolf
C
, et al
.
Assessment of intestinal vascular malformations in patients with hereditary hemorrhagic teleangiectasia and anemia
.
Eur J Gastroenterol Hepatol
.
2007
;
19
(
2
):
153
-
158
.
36.
Grève
E
,
Moussata
D
,
Gaudin
JL
, et al
.
High diagnostic and clinical impact of small-bowel capsule endoscopy in patients with hereditary hemorrhagic telangiectasia with overt digestive bleeding and/or severe anemia
.
Gastrointest Endosc
.
2010
;
71
(
4
):
760
-
767
.
37.
Canzonieri
C
,
Centenara
L
,
Ornati
F
, et al
.
Endoscopic evaluation of gastrointestinal tract in patients with hereditary hemorrhagic telangiectasia and correlation with their genotypes
.
Genet Med
.
2014
;
16
(
1
):
3
-
10
.
38.
Kjeldsen
AD
,
Kjeldsen
J
.
Gastrointestinal bleeding in patients with hereditary hemorrhagic telangiectasia
.
Am J Gastroenterol
.
2000
;
95
(
2
):
415
-
418
.
39.
Iyer
VN
,
Brinjikji
W
,
Apala
D
, et al
.
Impact of Age on Outcomes in Hospitalized Patients with Hereditary Hemorrhagic Telangiectasia
.
Adv Hematol
.
2018
;
2018
:
4798425
.
40.
Zaffar
N
,
Ravichakaravarthy
T
,
Faughnan
ME
,
Shehata
N
.
The use of anti-fibrinolytic agents in patients with HHT: a retrospective survey
.
Ann Hematol
.
2015
;
94
(
1
):
145
-
152
.
41.
Shovlin
CL
,
Awan
I
,
Cahilog
Z
,
Abdulla
FN
,
Guttmacher
AE
.
Reported cardiac phenotypes in hereditary hemorrhagic telangiectasia emphasize burdens from arrhythmias, anemia and its treatments, but suggest reduced rates of myocardial infarction
.
Int J Cardiol
.
2016
;
215
:
179
-
185
.
42.
Kasthuri
RS
,
Montifar
M
,
Nelson
J
,
Kim
H
,
Lawton
MT
,
Faughnan
ME
;
Brain Vascular Malformation Consortium HHT Investigator Group
.
Prevalence and predictors of anemia in hereditary hemorrhagic telangiectasia
.
Am J Hematol
.
2017
;
92
(
10
):
E591
-
E593
.
43.
Thielemans
L
,
Layton
DM
,
Shovlin
CL
.
Low serum haptoglobin and blood films suggest intravascular hemolysis contributes to severe anemia in hereditary hemorrhagic telangiectasia
.
Haematologica
.
2019
;
104
(
4
):
e127
-
e130
.
44.
Plauchu
H
,
de Chadarévian
JP
,
Bideau
A
,
Robert
JM
.
Age-related clinical profile of hereditary hemorrhagic telangiectasia in an epidemiologically recruited population
.
Am J Med Genet
.
1989
;
32
(
3
):
291
-
297
.
45.
Kettaneh
A
,
Eclache
V
,
Fain
O
, et al
.
Pica and food craving in patients with iron-deficiency anemia: a case-control study in France
.
Am J Med
.
2005
;
118
(
2
):
185
-
188
.
46.
Vaucher
P
,
Druais
PL
,
Waldvogel
S
,
Favrat
B
.
Effect of iron supplementation on fatigue in nonanemic menstruating women with low ferritin: a randomized controlled trial
.
CMAJ
.
2012
;
184
(
11
):
1247
-
1254
.
47.
Trost
LB
,
Bergfeld
WF
,
Calogeras
E
.
The diagnosis and treatment of iron deficiency and its potential relationship to hair loss
.
J Am Acad Dermatol
.
2006
;
54
(
5
):
824
-
844
.
48.
Haas
JD
,
Brownlie
Tt
.
Iron deficiency and reduced work capacity: a critical review of the research to determine a causal relationship
.
J Nutr
.
2001
;
131
(
2S-2
):
676S
-
688S
;
discussion 688S-690S
.
49.
Livesey
JA
,
Manning
RA
,
Meek
JH
, et al
.
Low serum iron levels are associated with elevated plasma levels of coagulation factor VIII and pulmonary emboli/deep venous thromboses in replicate cohorts of patients with hereditary haemorrhagic telangiectasia
.
Thorax
.
2012
;
67
(
4
):
328
-
333
.
50.
Shovlin
CL
,
Sulaiman
NL
,
Govani
FS
,
Jackson
JE
,
Begbie
ME
.
Elevated factor VIII in hereditary haemorrhagic telangiectasia (HHT): association with venous thromboembolism
.
Thromb Haemost
.
2007
;
98
(
5
):
1031
-
1039
.
51.
Shovlin
CL
.
Circulatory contributors to the phenotype in hereditary hemorrhagic telangiectasia
.
Front Genet
.
2015
;
6
:
101
.
52.
Edwards
CP
,
Shehata
N
,
Faughnan
ME
.
Hereditary hemorrhagic telangiectasia patients can tolerate anticoagulation
.
Ann Hematol
.
2012
;
91
(
12
):
1959
-
1968
.
53.
Devlin
HL
,
Hosman
AE
,
Shovlin
CL
.
Antiplatelet and anticoagulant agents in hereditary hemorrhagic telangiectasia
.
N Engl J Med
.
2013
;
368
(
9
):
876
-
878
.
54.
Shovlin
CL
,
Millar
CM
,
Droege
F
, et al;
VASCERN-HHT
.
Safety of direct oral anticoagulants in patients with hereditary hemorrhagic telangiectasia
.
Orphanet J Rare Dis
.
2019
;
14
(
1
):
210
.
55.
Gaetani
E
,
Agostini
F
,
Porfidia
A
, et al;
Multidisciplinary Gemelli Group for HHT
.
Safety of antithrombotic therapy in subjects with hereditary hemorrhagic telangiectasia: prospective data from a multidisciplinary working group
.
Orphanet J Rare Dis
.
2019
;
14
(
1
):
298
.
56.
Albiñana
V
,
Recio-Poveda
L
,
Zarrabeitia
R
,
Botella
LM
.
Current and emerging pharmacotherapies for hereditary hemorrhagic telangiectasia
.
Expert Opin Orphan Drugs
.
2017
;
5
(
8
):
665
-
675
.
57.
Ruiz-Llorente
L
,
Gallardo-Vara
E
,
Rossi
E
,
Smadja
DM
,
Botella
LM
,
Bernabeu
C
.
Endoglin and alk1 as therapeutic targets for hereditary hemorrhagic telangiectasia [published correction appears in Expert Opin Ther Targets. 2017;21(10):995.]
.
Expert Opin Ther Targets
.
2017
;
21
(
10
):
933
-
947
.
58.
Zacharski
LR
,
Dunbar
SD
,
Newsom
WA
Jr
.
Hemostatic effects of tamoxifen in hereditary hemorrhagic telangiectasia
.
Thromb Haemost
.
2001
;
85
(
2
):
371
-
372
.
59.
Jameson
JJ
,
Cave
DR
.
Hormonal and antihormonal therapy for epistaxis in hereditary hemorrhagic telangiectasia
.
Laryngoscope
.
2004
;
114
(
4
):
705
-
709
.
60.
Helmi
AM
,
El Ghazzawi
IF
,
Mandour
MA
,
Shehata
MA
.
The effect of oestrogen on the nasal respiratory mucosa. An experimental histopathological and histochemical study
.
J Laryngol Otol
.
1975
;
89
(
12
):
1229
-
1241
.
61.
Beckman
JD
,
Li
Q
,
Hester
ST
,
Leitner
O
,
Smith
KL
,
Kasthuri
RS
.
Integration of clinical parameters, genotype and epistaxis severity score to guide treatment for hereditary hemorrhagic telangiectasia associated bleeding
.
Orphanet J Rare Dis
.
2020
;
15
(
1
):
185
.
62.
Buscarini
E
,
Botella
LM
,
Geisthoff
U
, et al;
VASCERN-HHT
.
Safety of thalidomide and bevacizumab in patients with hereditary hemorrhagic telangiectasia
.
Orphanet J Rare Dis
.
2019
;
14
(
1
):
28
.
63.
Albitar
HAH
,
Almodallal
Y
,
Gallo De Moraes
A
, et al
.
Intravenous Bevacizumab in Hereditary Hemorrhagic Telangiectasia-Related Bleeding and High-Output Cardiac Failure: Significant Inter-Individual Variability in the Need for Maintenance Therapy
.
Mayo Clin Proc
.
2020
;
95
(
8
):
1604
-
1612
.
64.
Al-Samkari
H
,
Albitar
HA
,
Olitsky
SE
,
Clancy
MS
,
Iyer
VN
.
An international survey to evaluate systemic bevacizumab for chronic bleeding in hereditary haemorrhagic telangiectasia [published online ahead of print 20 May 2020]
.
Haemophilia
.
doi:10.1111/hae.14034
.
65.
Al-Samkari
H
,
Albitar
HA
,
Olitsky
SE
,
Clancy
MS
,
Iyer
VN
.
Systemic bevacizumab for high-output cardiac failure in hereditary hemorrhagic telangiectasia: an international survey of HHT centers
.
Orphanet J Rare Dis
.
2019
;
14
(
1
):
256
.
66.
Kroon
S
,
Snijder
RJ
,
Mager
JJ
, et al
.
Octreotide for gastrointestinal bleeding in hereditary hemorrhagic telangiectasia: A prospective case series
.
Am J Hematol
.
2019
;
94
(
9
):
E247
-
E249
.
67.
Houghton
KD
,
Umar
B
,
Schairer
J
.
Successful Treatment of Hereditary Hemorrhagic Telangiectasia With Octreotide
.
ACG Case Rep J
.
2019
;
6
(
6
):
e00088
.
68.
Jeanneret
S
,
Regazzoni
L
,
Favrat
B
.
Rendu-Osler disease: treatment with oestrogen/progestagen versus octreotide
.
BMJ Case Rep
.
2011
;
2011
:
bcr1120103534
.
69.
Albiñana
V
,
Sanz-Rodríguez
F
,
Recio-Poveda
L
,
Bernabéu
C
,
Botella
LM
.
Immunosuppressor FK506 increases endoglin and activin receptor-like kinase 1 expression and modulates transforming growth factor-β1 signaling in endothelial cells
.
Mol Pharmacol
.
2011
;
79
(
5
):
833
-
843
.
70.
Sommer
N
,
Droege
F
,
Gamen
KE
, et al
.
Treatment with low-dose tacrolimus inhibits bleeding complications in a patient with hereditary hemorrhagic telangiectasia and pulmonary arterial hypertension
.
Pulm Circ
.
2019
;
9
(
2
):
2045894018805406
.
71.
Hosman
AE
,
Kroon
S
,
Vorselaars
V
, et al
.
Tacrolimus treatment for two rare complications caused by hereditary haemorrhagic telangiectasia: A description of two cases
.
Angiogenesis
.
2019
;
22
:
629
.
72.
Ruiz
S
,
Zhao
H
,
Chandakkar
P
, et al
.
Correcting Smad1/5/8, mTOR, and VEGFR2 treats pathology in hereditary hemorrhagic telangiectasia models
.
J Clin Invest
.
2020
;
130
(
2
):
942
-
957
.
73.
Dupuis-Girod
S
,
Chesnais
AL
,
Ginon
I
, et al
.
Long-term outcome of patients with hereditary hemorrhagic telangiectasia and severe hepatic involvement after orthotopic liver transplantation: a single-center study
.
Liver Transpl
.
2010
;
16
(
3
):
340
-
347
.
74.
Crist
AM
,
Zhou
X
,
Garai
J
, et al
.
Angiopoietin-2 Inhibition Rescues Arteriovenous Malformation in a Smad4 Hereditary Hemorrhagic Telangiectasia Mouse Model
.
Circulation
.
2019
;
139
(
17
):
2049
-
2063
.
75.
Ola
R
,
Dubrac
A
,
Han
J
, et al
.
PI3 kinase inhibition improves vascular malformations in mouse models of hereditary haemorrhagic telangiectasia
.
Nat Commun
.
2016
;
7
(
1
):
13650
.
76.
Samour
M
,
Saygin
C
,
Abdallah
R
,
Kundu
S
,
McCrae
KR
.
Pomalidomide in Hereditary Hemorrhagic Telangiectasia: Interim Results of a Phase I Study [abstract]
.
Blood
.
2016
;
128
(
22
). Abstract 210.
77.
Faughnan
ME
,
Gossage
JR
,
Chakinala
MM
, et al
.
Pazopanib may reduce bleeding in hereditary hemorrhagic telangiectasia
.
Angiogenesis
.
2019
;
22
(
1
):
145
-
155
.
78.
Kovacs-Sipos
E
,
Holzmann
D
,
Scherer
T
,
Soyka
MB
.
Nintedanib as a novel treatment option in hereditary haemorrhagic telangiectasia
.
BMJ Case Rep
.
2017
;
2017
:
21932
.
79.
Ganzoni
AM
.
[Intravenous iron-dextran: therapeutic and experimental possibilities]
.
Schweiz Med Wochenschr
.
1970
;
100
(
7
):
301
-
303
.
80.
Vorselaars
VM
,
Velthuis
S
,
Swaans
MJ
, et al
.
Percutaneous left atrial appendage closure-An alternative strategy for anticoagulation in atrial fibrillation and hereditary hemorrhagic telangiectasia?
Cardiovasc Diagn Ther
.
2015
;
5
(
1
):
49
-
53
.
You do not currently have access to this content.

Sign in via your Institution

Sign In